ModerateShort-acting systemic glucocorticoid, identical to endogenous cortisol×Amide-type local anaesthetic and class Ib antiarrhythmic (systemic use, codes C01BB01 and N01BB02)
Updated · Methodology
Mechanism
11-beta-hydroxysteroid dehydrogenase type 2 and CYP3A4 metabolise hydrocortisone (hydrocortisone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, CYP1A2 and CYP3A4 are the main enzymes that metabolise lidocaine (lidocaine SmPC, AEMPS; lidocaine label, US Food and Drug Administration, FDA). According to the SmPC of one Spanish hydrocortisone injection (Hidrocortisona Normon), another CYP3A4 substrate may change the hepatic clearance of hydrocortisone, with corresponding dose adjustments. The adverse effects of either drug may also become more likely (hydrocortisone SmPC, AEMPS). The SmPCs of the original Spanish hydrocortisone products and the US label do not contain this statement (AEMPS, FDA). The documents do not address hydrocortisone with lidocaine specifically. Separately, hydrocortisone can increase potassium excretion (hydrocortisone SmPC, AEMPS). When large doses of lidocaine are used for arrhythmias, hypokalaemia is corrected beforehand (lidocaine SmPC, AEMPS).
Symptoms
The documents describe no symptoms specific to this combination. When used for arrhythmias, lidocaine commonly causes nausea, vomiting, drowsiness, dizziness, tinnitus, tingling of the skin and confusion. Rarely, it causes muscle spasms that can progress to seizures, a slow heart rate and heart block (lidocaine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hydrocortisone can raise blood pressure, cause salt and water retention and increase potassium excretion. Its adverse effects include hypokalaemic alkalosis (hydrocortisone SmPC, AEMPS).
Management
No document contraindicates the combination, and none addresses it directly. Lidocaine is a CYP3A4 substrate (lidocaine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Hidrocortisona Normon SmPC, another CYP3A4 substrate may change hydrocortisone clearance, and doses are then adjusted (hydrocortisone SmPC, AEMPS). Lidocaine is given at the lowest dose that produces the desired effect. For local anaesthesia in tissues with high systemic absorption, a single dose does not exceed 400 mg (lidocaine SmPC, AEMPS). In intravenous treatment of arrhythmias, hypokalaemia, hypoxia and acid-base disorders are corrected before large doses of lidocaine are given. During prolonged infusion, fluid balance, electrolytes and acid-base balance are monitored regularly. The electrocardiogram (ECG), blood pressure, consciousness and breathing are monitored continuously (lidocaine SmPC, AEMPS). Hydrocortisone can increase potassium excretion, so salt restriction and potassium supplements may be needed (hydrocortisone SmPC, AEMPS). With the medicated lidocaine plaster, blood concentrations are low, and a clinically relevant pharmacokinetic interaction is unlikely (lidocaine plaster SmPC, AEMPS). The documents give no specific lidocaine dose adjustment for hydrocortisone (lidocaine SmPC, AEMPS; lidocaine label, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Lidocaine Hydrochloride and Dextrose Injection, USP – Prescribing Information (2026)– FDA, DailyMed SPL, Baxter Healthcare, sections Indications and Usage, Contraindications and Drug Interactions
- AEMPS: Ficha técnica: Lidocaína – Lidocaína B. Braun 20 mg/ml (nº registro 44792), sección 4.5 (2021)– AEMPS, CIMA, nº registro 44792 (Lidocaína B. Braun 20 mg/ml solución inyectable), revisión 07/2021, secciones 4.1, 4.2, 4.4, 4.5, 4.9 y 5.2
- AEMPS: Ficha técnica: Lidocaína – Versatis 700 mg apósito (nº registro 71848), sección 4.5 (2019)– AEMPS, CIMA, nº registro 71848 (Versatis 700 mg apósito adhesivo medicamentoso, Grünenthal), revisión 01/2019, secciones 4.5 y 5.2
- AEMPS: Ficha técnica: Hidrocortisona – Hidrocortisona Normon 100 mg (nº registro 90505), sección 4.5 (2025)– AEMPS, CIMA, nº registro 90505 (Hidrocortisona Normon 100 mg polvo y disolvente para solución inyectable y para perfusión EFG), revisión 11/2025, secciones 4.4, 4.5 y 4.8
- FDA: SOLU-CORTEF (hydrocortisone sodium succinate) prescribing information (2026)– FDA, DailyMed setid 65eefd58-b166-4d71-ade6-45c8fdf86922 (Pharmacia & Upjohn, Pfizer), version 31, revised 09/2026, Warnings; Precautions: Drug Interactions; Adverse Reactions